Recro Pharma has announced positive results from its second of two Phase III clinical trials evaluating N 1539 (intravenous meloxicam)...
Recro Pharma, Inc. announced the publication of new intravenous (IV) meloxicam data. The article, titled �Meloxicam intravenous for the treatment...
Recro Pharma, Inc. announced a poster presentation highlighting intravenous (IV) meloxicam's effect on platelet function at the 72nd PostGraduate Assembly...
Recro Pharma, Inc. announced the publication of previously reported Phase II clinical data for intravenous (IV) meloxicam for the treatment...